Education
About Us
Working with TipRanks
Follow Us
Imugene (IUGNF)
OTHER OTC:IUGNF
IUGNF Stock Chart & Stats
$0.22
>-$0.01(-3.57%)
At close: 4:00 PM EST
$0.22
>-$0.01(-3.57%)
Day’s Range― - ―
52-Week Range$0.03 - $1.47
Previous CloseN/A
Volume3.00K
Average Volume (3M)16.82K
Market Cap
$63.69M
Enterprise Value$85.79M
Total Cash (Recent Filing)$21.94M
Total Debt (Recent Filing)$10.65M
Price to Earnings (P/E)―
Beta0.35
Next Earnings
Mar 04, 2026EPS Estimate
-0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding315,377,870
10 Day Avg. Volume10,335
30 Day Avg. Volume16,823
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)2.15
Price to Sales (P/S)21.99
P/FCF Ratio-1.07
Enterprise Value/Market Cap1.35
Enterprise Value/Revenue19.51
Enterprise Value/Gross Profit19.51
Enterprise Value/Ebitda-1.27
Forecast
1Y Price Target
$0.54Price Target Upside145.45% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Imugene News
IUGNF FAQ
What was Imugene’s price range in the past 12 months?
Imugene lowest stock price was $0.03 and its highest was $1.47 in the past 12 months.
What is Imugene’s market cap?
Imugene’s market cap is $63.69M.
When is Imugene’s upcoming earnings report date?
Imugene’s upcoming earnings report date is Mar 04, 2026 which is in 71 days.
How were Imugene’s earnings last quarter?
Imugene released its earnings results on Aug 27, 2025. The company reported -$0.063 earnings per share for the quarter, beating the consensus estimate of -$0.227 by $0.164.
Is Imugene overvalued?
According to Wall Street analysts Imugene’s price is currently Undervalued.
Does Imugene pay dividends?
Imugene does not currently pay dividends.
What is Imugene’s EPS estimate?
Imugene’s EPS estimate is -0.23.
How many shares outstanding does Imugene have?
Imugene has 315,377,870 shares outstanding.
What happened to Imugene’s price movement after its last earnings report?
Imugene reported an EPS of -$0.063 in its last earnings report, beating expectations of -$0.227. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Imugene?
Currently, no hedge funds are holding shares in IUGNF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Imugene Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$0.54 (145.45% Upside)
$0.54 (145.45% Upside)
Blogger Sentiment
Bullish
IUGNF Sentiment 77%
Sector Average ―
Sector Average ―
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-73.03%
12-Months-Change
Fundamentals
Return on Equity
-83.09%
Trailing 12-Months
Asset Growth
-45.82%
Trailing 12-Months
Company Description
Imugene
Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; and CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. The company has a research collaboration with Celularity Inc. to develop the combination of Imugene's CD19 oncolytic virus technology and Celularity's CD19 targeting allogeneic chimeric antigen receptor T-cell therapy, CyCART-19 for the treatment of solid tumors; and has a strategic collaboration with Eureka Therapeutics, Inc. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia.
IUGNF Stock 12 Month Forecast
Average Price Target
$0.54
▲(145.45% Upside)
Technical Analysis
Paradigm Biopharmaceuticals
―
Alterity Therapeutics
―
Prescient Therapeutics Limited
―
Recce Pharmaceuticals Ltd.
―
Arovella Therapeutics Limited
―
Ownership Overview
4.94% Insiders
2.40% Mutual Funds
― Other Institutional Investors
92.66% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---